|
GSK and Theravance Announce Regulatory Submissions for FF/VI in the US and …
MarketWatch (press release) Asthma (100/25mcg and 200/25mcg): The regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate. COPD (100/25mcg): The … GSK, Theravance unveil Regulatory Submissions for FF/VI in US, Europe GSK files key new lung drug for regulatory approval |
View full post on asthma – Google News